Project Grant R21CA314402
Award Date 6/10/26
Completion Date 5/31/28
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $624,194 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026, through March 31, 2031. This award supports fundamental research investigating the regulation of immunometabolism by the Integrated Stress Response (ISR) in cancer, with specific focus on how chronic activation of Activating Transcription Factor 4 (ATF4) impairs...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $2,554,662 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) beginning March 5, 2026 through February 28, 2031. This comprehensive research initiative focuses on developing biomaterial-enhanced chimeric antigen receptor (CAR) T-cell and natural killer T-cell therapies to improve treatment outcomes for glioblastoma, an aggressive brain tumor with...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $399,829 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) to establish the feasibility of developing a population-based hepatocellular carcinoma (HCC) surveillance registry and assess the identification of at-risk patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The award, effective May 15, 2026 through April...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $207,802 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective May 1, 2026 through April 30, 2029. This award supports the development of multiplexed multiscale imaging technologies and automated analysis systems to advance cellular immunotherapy research. The project will deliver two primary products: (1) development of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded the University of Illinois a $412,249 Project Grant effective June 5, 2026, through May 31, 2028, to develop precision liver cancer modeling through CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) editing of primary human hepatocytes. The research addresses critical limitations in current hepatocellular carcinoma (HCC) models by creating a versatile platform that...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $628,539 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, through June 30, 2031. This award supports the development of novel small molecule inhibitors targeting the deubiquitinase OTUD7A as a therapeutic strategy for Ewing sarcoma, an aggressive malignancy affecting children and young adults. The research team will utilize...
- Federal Project Grant Award Summary The National Cancer Institute awarded the University of North Carolina at Chapel Hill $394,214 under the Cancer Biology Research program (CFDA 93.396) to develop transgenic mouse models and novel cell culture reagents for Epstein-Barr virus (EBV)-driven solid tumors. The award, effective May 19, 2026, through April 30, 2028, addresses a critical research gap by creating immunocompetent transgenic mice carrying the complete EBV genome to model epithelial...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...